MwanzoGNLX • NASDAQ
add
Genelux Corp
$ 4.55
Baada ya Saa za Kazi:(1.64%)+0.074
$ 4.62
Imefungwa: 2 Jan, 17:51:25 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 4.36
Bei za siku
$ 4.41 - $ 4.61
Bei za mwaka
$ 1.99 - $ 8.54
Thamani ya kampuni katika soko
173.14M USD
Wastani wa hisa zilizouzwa
elfu 149.08
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 8.19M | 18.05% |
Mapato halisi | -7.95M | -22.93% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.21 | -10.53% |
EBITDA | -8.13M | -18.11% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 20.92M | -38.59% |
Jumla ya mali | 24.99M | -37.95% |
Jumla ya dhima | 6.40M | -10.91% |
Jumla ya hisa | 18.59M | — |
hisa zilizosalia | 37.62M | — |
Uwiano wa bei na thamani | 8.90 | — |
Faida inayotokana na mali | -71.58% | — |
Faida inayotokana mtaji | -89.42% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -7.95M | -22.93% |
Pesa kutokana na shughuli | -6.58M | -14.39% |
Pesa kutokana na uwekezaji | 4.72M | 18.26% |
Pesa kutokana na ufadhili | 0.00 | — |
Mabadiliko halisi ya pesa taslimu | -1.85M | -5.58% |
Mtiririko huru wa pesa | -4.10M | -27.13% |
Kuhusu
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Ilianzishwa
2001
Makao Makuu
Tovuti
Wafanyakazi
24
